Open Access

ARTICLE

The Implication of microRNAs as non-invasive biomarkers in 179 Egyptian breast cancer female patients

NADIA Z. SHAABAN¹, NASHWA K. IBRAHIM², HELEN N. SAADA², FATMA H. EL-RASHIDY¹, HEBATALLAH M. SHAABAN³, NERMEEN M. ELBAKARY^2,*, AHMAD S. KODOUS^1,2,*

1 Biochemistry Department, Faculty of Science, Alexandria University, P.O. Box 21568, Alexandria, Egypt
2 Radiation Biology Department, National Center for Radiation Research & Technology, Egyptian Atomic-Energy Authority, P.O. Box 8029, Cairo, Egypt
3 National Cancer Institute, Cairo University, P.O. Box 11796, Cairo, Egypt

* Corresponding Authors: Ahmad S. Kodous, ; Nermeen M. Elbakary,

Oncology Research 2022, 30(6), 269-276. https://doi.org/10.32604/or.2022.027277

Received 22 October 2022; Accepted 09 January 2023; Issue published 09 February 2023

Abstract

Background: MicroRNAs (miRs) are small (19–25 nucleotides), non-protein coding RNAs that regulate gene expression, and thus play essential roles in cell cycle progression. The evidence has demonstrated that the expression of several miRs is dysregulated in human cancer. Methods: The study includes 179 female patients and 58 healthy women Patients were identified as luminal A, B, Her-2/neu, and basal-like, as well as classified into I, II, and III stages. Analysis of the expression fold change of miR-21 and miR-34a with molecular markers, including the oncogene Bcl-2 (B-cell lymphoma 2) and the tumor suppressor genes BRCA1 (breast cancer susceptibility gene 1), BRCA2 (breast cancer susceptibility gene 2), and the tumor suppressor protein p53, was carried out for all patients, pre- and postchemotherapy, and for all healthy women. Results: At diagnosis (pre-chemotherapy), miR-21 was up-regulated (p < 0.001), while miR-34a was down-regulated (p < 0.001). Post-chemotherapy, the expression of miR-21 decreased significantly (p < 0.001), while the expression of miR-34a increased significantly (p < 0.001). Conclusion: miR-21 and miR-34a may be helpful to non-invasive biomarkers to evaluate the response of breast cancer to chemotherapy.

---

Keywords

---